LEGN vs. ONC, BNTX, TEVA, SMMT, ITCI, MRNA, GMAB, RDY, VTRS, and ASND
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Legend Biotech vs.
Legend Biotech (NASDAQ:LEGN) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Legend Biotech received 84 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 71.90% of users gave Legend Biotech an outperform vote while only 60.00% of users gave Beigene an outperform vote.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 48.5% of Beigene shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 7.4% of Beigene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Legend Biotech has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Beigene has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
Beigene has a net margin of -25.94% compared to Legend Biotech's net margin of -66.92%. Beigene's return on equity of -25.12% beat Legend Biotech's return on equity.
Legend Biotech has higher earnings, but lower revenue than Beigene. Legend Biotech is trading at a lower price-to-earnings ratio than Beigene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Legend Biotech had 5 more articles in the media than Beigene. MarketBeat recorded 9 mentions for Legend Biotech and 4 mentions for Beigene. Legend Biotech's average media sentiment score of 1.43 beat Beigene's score of 0.84 indicating that Legend Biotech is being referred to more favorably in the media.
Legend Biotech presently has a consensus price target of $79.00, suggesting a potential upside of 123.23%. Beigene has a consensus price target of $310.00, suggesting a potential upside of 18.05%. Given Legend Biotech's higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Beigene.
Summary
Legend Biotech beats Beigene on 10 of the 18 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:LEGN) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy LEGN Stock Free LEGN Stock Alerts